Literature DB >> 15546811

Increased intestinal permeability in patients with inflammatory bowel disease.

K Welcker1, A Martin, P Kölle, M Siebeck, M Gross.   

Abstract

Intestinal permeability can be measured by the sugar absorption test. This test is based on determining the ratio of the urinary excretion of a large and a small carbohydrate after oral administration. The aim of this study was to determine which combination of carbohydrates used in the test gives the highest correlation with disease activity in inflammatory bowel disease. 26 patients with Crohn's disease, 21 patients with ulcerative colitis and 27 healthy control subjects were included in the study. The patients with inflammatory bowel disease had either minimal or highly active disease or were in remission. Two disaccharides (lactulose: L, and cellobiose: C) and two smaller carbohydrates (rhamnose:R, and mannitol:M) were given orally and the urinary excretion was measured by high pressure liquid chromatography followed by pulsed amperometric electrochemical detection on a gold electrode. The ratios C/R, L/R, C/M and L/M were used as indicators for intestinal permeability. - There were no side effects of oral sugar administration. All patients tolerated the test well. Lactulose, rhamnose and cellobiose concentrations are easily be measured in the urine whereas mannitol measurement requires the use of an anion exchanger. This produced inconsistent results. Patients with Crohn's disease or with ulcerative colitis had increased permeability indices in comparison to healthy controls, even in remission. The L/R ratio gave a better differentiation between the healthy controls and patients with active disease than the other agents. Changes in disease activity are best reflected by use of cellobiose/rhamnose excretion quotient.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15546811

Source DB:  PubMed          Journal:  Eur J Med Res        ISSN: 0949-2321            Impact factor:   2.175


  37 in total

Review 1.  Intestinal epithelial cells in inflammatory bowel diseases.

Authors:  Giulia Roda; Alessandro Sartini; Elisabetta Zambon; Andrea Calafiore; Margherita Marocchi; Alessandra Caponi; Andrea Belluzzi; Enrico Roda
Journal:  World J Gastroenterol       Date:  2010-09-14       Impact factor: 5.742

2.  Rho activation regulates CXCL12 chemokine stimulated actin rearrangement and restitution in model intestinal epithelia.

Authors:  Rebecca A Moyer; Michael K Wendt; Priscilla A Johanesen; Jerrold R Turner; Michael B Dwinell
Journal:  Lab Invest       Date:  2007-06-18       Impact factor: 5.662

Review 3.  Potential for developing purinergic drugs for gastrointestinal diseases.

Authors:  Fernando Ochoa-Cortes; Andromeda Liñán-Rico; Kenneth A Jacobson; Fievos L Christofi
Journal:  Inflamm Bowel Dis       Date:  2014-07       Impact factor: 5.325

4.  Increased intestinal permeability in inflammatory bowel diseases assessed by iohexol test.

Authors:  Vanya A Gerova; Simeon G Stoynov; Dimitar S Katsarov; Dobrin A Svinarov
Journal:  World J Gastroenterol       Date:  2011-05-07       Impact factor: 5.742

5.  Effects of timing, sex, and age on site-specific gastrointestinal permeability testing in children and adults.

Authors:  Mark E McOmber; Ching-Nan Ou; Robert J Shulman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2010-03       Impact factor: 2.839

Review 6.  Emerging neuropeptide targets in inflammation: NPY and VIP.

Authors:  Bindu Chandrasekharan; Behtash Ghazi Nezami; Shanthi Srinivasan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-03-28       Impact factor: 4.052

Review 7.  Campylobacter concisus and inflammatory bowel disease.

Authors:  Li Zhang; Hoyul Lee; Michael C Grimm; Stephen M Riordan; Andrew S Day; Daniel A Lemberg
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

Review 8.  Intestinal barrier in inflammatory bowel disease.

Authors:  Lena Antoni; Sabine Nuding; Jan Wehkamp; Eduard F Stange
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

Review 9.  Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies.

Authors:  James H Tabibian; Steven P O'Hara; Keith D Lindor
Journal:  Scand J Gastroenterol       Date:  2014-07-03       Impact factor: 2.423

10.  Myosin light chain kinase inhibition: correction of increased intestinal epithelial permeability in vitro.

Authors:  Linda M Feighery; Sean W Cochrane; Teresa Quinn; Alan W Baird; Daniel O'Toole; Sian-Eleri Owens; Diarmuid O'Donoghue; Randall J Mrsny; David J Brayden
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.